Saturday 17 October 2026 Export BNR’s income statement to Excel — free account

Burning Rock Biotech Limited Sponsored ADR

Burning Rock Biotech Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $77.2 million, up 9.18% from fiscal 2024. In the quarter to June 2026, revenue fell 4.22%, EPS fell 98.4%, free cash flow grew 46.0% and total debt fell 5.02%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

12.69 2.91 −18.65%

Follow BNR

Alert me

Market cap: $137.1M
P/E: 0.0×
Fwd P/E: 11.1×
Dividend yield: —
F-score: 5/9
Altman Z: −2.95
Beneish M: −2.47
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 11.65

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	—	1	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 91.93%

Capital & Financial Ratios $m

Market Cap 137.12

Revenue 73.59

Net Income (7.92)

Free Cash Flow (2.21)

Net Debt (61.50)

Current Ratio 3.05

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 11.10

P/S ratio 18.73

P/B ratio 18.81

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth 3,217.16%

Next 5Y EPS Growth 5.10%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 76.70%

10-year low 10-year high

P/B against its own 10 years 92.36%

10-year low 10-year high

EV/Sales against its own 10 years 77.00%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	87	72	69	62
Receivables	18	21	24	25
Inventory	10	9	7	5
Other	3	2	3	2
	125	106	106	98

	2023	2024	2025	Q'26
Payables	3	5	6	3
ST’ Debt	—	—	0	0
Other	0	0	0	0
	37	36	35	32

Compound Annual Growth %

	10y	5y	3y
Sales	—	3.21%	(1.87%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(27.07%)	(23.04%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	16	20	—	—	—
’25	18	21	18	20	77
’24	17	19	18	16	71
’23	21	20	17	17	76
’22	21	20	22	19	82
’21	16	20	20	24	80
’20	10	15	18	20	66

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(3)	—	—	—
’25	(3)	(6)	2	3	(4)
’24	(6)	(6)	(5)	3	(13)
’23	(16)	(10)	(6)	(3)	(36)
’22	(23)	(15)	(17)	(12)	(66)
’21	(17)	(19)	(21)	(18)	(75)
’20	(1)	9	3	(13)	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(3)	—	—	—
’25	(3)	(6)	2	3	(5)
’24	(6)	(6)	(5)	3	(13)
’23	(16)	(10)	(6)	(3)	(37)
’22	(23)	(15)	(17)	(12)	(76)
’21	(17)	(19)	(21)	(18)	(108)
’20	(1)	9	3	(13)	(23)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.02)	(0.02)	—	—	—
’25	(0.02)	(0.01)	(0.26)	(0.21)	(0.73)
’24	(0.16)	(0.14)	(0.05)	(1.08)	(4.61)
’23	(2.60)	(1.80)	(2.30)	(2.20)	(9.00)
’22	(3.90)	(3.70)	(3.10)	(3.10)	(13.60)
’21	(2.50)	(3.00)	(2.50)	(3.80)	(12.00)
’20	(0.11)	(2.47)	(1.80)	(0.23)	(10.50)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	186.40	92.70	17.00	6.89	2.62	2.18	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	324.00	397.50	112.70	38.00	9.99	24.18
People
People	Employees	—	—	—	753	938	1,394	1,138	786	674	667
	Revenue/emp, $m	—	0.00	0.00	0.07	0.07	0.06	0.07	0.10	0.10	0.12
Income, $m
Income, $m	Revenue	—	16	32	55	66	80	82	76	71	77
	Gross margin, %	—	64.49	64.66	71.61	73.02	71.70	67.47	67.58	70.25	74.67
	EBT	—	(19)	(27)	(24)	(62)	(125)	(141)	(92)	(47)	(8)
	EBT margin, %	—	(118.09)	(84.98)	(44.32)	(94.73)	(156.70)	(172.08)	(121.19)	(66.06)	(9.97)
	Net income	—	0	(27)	0	(62)	(125)	(141)	(92)	(47)	(8)
	Depreciation	—	3	4	5	5	7	18	19	7	3
Per share, $
Per share, $	Revenue	—	0.16	0.30	0.53	9.60	7.65	7.86	7.39	6.87	7.26
	Earnings	—	(0.26)	(0.34)	(0.47)	(10.50)	(12.00)	(13.60)	(9.00)	(4.61)	(0.73)
	Cash flow	—	(0.19)	(0.22)	(0.32)	(1.64)	(7.20)	(6.37)	(3.52)	(1.23)	(0.38)
	Capex	—	0.00	0.00	0.00	(1.76)	(3.21)	(0.95)	(0.13)	(0.06)	(0.06)
	Free cash flow	—	(0.19)	(0.22)	(0.32)	(3.40)	(10.40)	(7.32)	(3.65)	(1.29)	(0.44)
	Book value	—	0.00	(0.01)	0.88	54.06	27.79	16.16	10.57	7.73	7.20
	Shares, m	—	104	104	104	7	10	10	10	10	11
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	0.00	0.00	0.00	381.27	12.46	2.75	1.31	0.98	2.78
	P/B	—	0.00	0.00	0.00	64.79	3.43	1.34	0.92	0.87	2.80
	EV/Sales	—	0.00	0.00	0.00	375.83	9.60	1.20	0.20	0.01	1.89
	EV/FCF	—	0.00	0.00	0.00	(8,207.08)	(10.21)	(1.47)	(0.17)	(0.02)	(8.83)
Cash, $m
Cash, $m	Operating cash flow	—	(20)	(22)	(33)	(11)	(75)	(66)	(36)	(13)	(4)
	Capex	—	(3)	(4)	(7)	(12)	(33)	(10)	(1)	(1)	(1)
	Free cash flow	—	(20)	(22)	(33)	(23)	(108)	(76)	(37)	(13)	(5)
Balance, $m
Balance, $m	Working capital	—	—	1	76	350	227	123	87	70	70
	Total debt	—	—	40	10	6	8	7	—	—	0
	Net debt	—	—	20	(49)	(344)	(228)	(127)	(87)	(72)	(69)
	Shareholders’ equity	—	—	(1)	91	371	290	168	108	80	77
Returns, %
Returns, %	ROA	—	0.00	(129.38)	(178.19)	(31.28)	(32.66)	(47.92)	(48.89)	(35.47)	(6.64)
	ROIC	—	—	0.00	0.00	(146.67)	(126.40)	(216.16)	(273.06)	(380.90)	(61.14)
	ROE	—	0.00	32.53	44.80	(59.51)	(37.85)	(61.56)	(66.68)	(50.57)	(10.14)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MYGN Myriad Genetics, Inc.	$416.1M	— (loss-making)	— (loss-making)	−10.51% (below 0%: shrinking)	n/m	+43.90% (above 0%: growing)	66.60%	(20.40%)	Compare
BDSX Biodesix, Inc.	$260.7M	— (loss-making)	— (loss-making)	+34.18% (above 0%: growing)	n/m	+72.75% (above 0%: growing)	82.06%	(20.06%)	Compare
XGN Exagen Inc.	$207.4M	— (loss-making)	— (loss-making)	+15.92% (above 0%: growing)	n/m	+211.34% (above 0%: growing)	61.27%	(8.64%)	Compare
BNR Burning Rock Biotech Limited Sponsored ADR	$137.1M	— (loss-making)	11.1×	−4.22% (below 0%: shrinking)	n/m	+46.01% (above 0%: growing)	72.58%	(13.36%)
MDXHF MedX Health Corp.	$103.2M	— (loss-making)	— (loss-making)	+33.59% (above 0%: growing)	n/m	+41.60% (above 0%: growing)	37.19%	(1,027.95%)	Compare
IMDX Insight Molecular Diagnostics Inc.	$100.1M	— (loss-making)	— (loss-making)	−53.86% (below 0%: shrinking)	n/m	−54.02% (below 0%: shrinking)	65.69%	(4,770.71%)	Compare
QUCY Quantum Cyber N.V	$95.1M	— (loss-making)	— (loss-making)	+11.12% (above 0%: growing)	n/m	+26.73% (above 0%: growing)	62.71%	0.00%	Compare
MDXH MDxHealth SA	$57.6M	— (loss-making)	— (loss-making)	+12.01% (above 0%: growing)	n/m	−200.20% (below 0%: shrinking)	65.75%	(18.74%)	Compare
MBAI MBody AI Ltd.	$47.4M	— (loss-making)	—	—	n/m	+122.08% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$101.7M	—	—	+12.01%	—	+42.75%	64.20%	(19.40%)

All 52 Diagnostics & Research stocks →

Burning Rock Biotech Limited Sponsored ADR (BNR) key facts

Strength: Burning Rock Biotech Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $77.2 million, up 9.18% from fiscal 2024.
Burning Rock Biotech Limited Sponsored ADR (BNR) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BNR traded at $12.69, a market capitalization of $137.1 million.
Return on equity was −10.1% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −2.95 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.